Miller-Rich v. Altum Pharmaceuticals Inc.

District Court, S.D. New York·Decided November 27, 2023·No. 1:22-cv-03473·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK NANCY MILLER-RICH, Plaintiff, -against- ALTUM PHARMACEUTICALS INC., Case No. 1:22-cv-03473 (JLR) BETTERLIFE PHARMA INC., AHMAD DOROUDIAN, STEPHEN DATTELS, KRISZTIAN OPINION AND ORDER TOTH, JOSEPH MIMRAN, JOHN AND JANE DOES 1-50, and ABC CORPORATIONS 1-20, Defendants. JENNIFER L. ROCHON, United States District Judge: Plaintiff Nancy Miller-Rich (“Plaintiff”) brings this action against Defendants Altum Pharmaceuticals Inc. (“Altum”), BetterLife Pharma Inc. (“BetterLife”), Ahmad Doroudian (“Doroudian”), Stephen Dattels (“Dattels”), Krisztian Toth (“Toth”), Joseph Mimran (“Mimran”), John and Jane Does 1-50 (the “Does”), and ABC Corporations 1-20 (the “Corporations”) (collectively, “Defendants”). ECF No. 50 (the “Amended Complaint” or “Am. Compl.”). Plaintiff asserts a securities-fraud claim against Altum and Doroudian under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. § 78j(b), and Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5. See Am. Compl. ¶¶ 78-81 (“Claim I”). Plaintiff also raises a common-law-fraud claim against Altum, BetterLife, Doroudian, Dattels, Toth, Mimran, the Does, and the Corporations, see id. ¶¶ 82-88 (“Claim II”); a common-law-fraud claim against only Altum and Doroudian, see id.

¶¶ 89-95 (“Claim III”); and two breach-of-contract claims against Altum, see id. ¶¶ 96-102 (“Claim IV”); id. ¶¶ 103-110 (“Claim V”). All of the claims relate to Plaintiff’s former employment at Altum and/or to Altum shares that she received while consulting for or employed by Altum. On March 3, 2023, Altum, BetterLife, and Doroudian (collectively, the “Altum Defendants”) moved to dismiss the Amended Complaint. ECF No. 63 (“Altum Br.”); see also ECF No. 77 (“Altum Reply”). That same day, Dattels also moved to dismiss the Amended Complaint. ECF No. 67-1 (“Dattels Br.”); see also ECF No. 78 (“Dattels Reply”). Plaintiff

opposes both motions. ECF No. 74 (“Opp.”). Plaintiff “also conditionally cross-moves for limited jurisdictional discovery in the event the Court determines that the evidence available at this preliminary stage is insufficient to make out a prima facie showing of personal jurisdiction.” Id. at 1. The Altum Defendants and Dattels oppose Plaintiff’s conditional cross-motion. See Altum Reply at 9-10; Dattels Reply at 10-11. Toth and Mimran have not appeared in this case (nor, unsurprisingly, have the unnamed Does or Corporations). For the reasons set forth below, the Court GRANTS the motions to dismiss and DENIES Plaintiff’s conditional cross-motion for jurisdictional discovery. BACKGROUND

I. Factual Allegations1 Plaintiff is a New York resident with decades of experience holding upper-level- management positions in the pharmaceutical, biotechnological, and healthcare industries.

1 In evaluating the motions to dismiss filed by the Altum Defendants and Dattels, the Court accepts the Amended Complaint’s factual allegations as true and draws all reasonable inferences in favor of Plaintiff. See Herrera v. Comme des Garcons, Ltd., 84 F.4th 110, 113 (2d Cir. 2023). The Court considers documents attached to the Amended Complaint or incorporated in the Amended Complaint by reference, as well as matters subject to judicial notice. See N.Y. Pet Welfare Ass’n v. City of New York, 850 F.3d 79, 86 (2d Cir. 2017). Where appropriate, the Court considers affidavits and attached exhibits submitted by the parties. See Van Cauwenberghe v. Biard, 486 U.S. 517, 529 (1988) (district court’s inquiry into forum non conveniens “may be resolved on affidavits presented by the parties”); Aguas Lenders Recovery Grp. v. Suez, S.A., 585 F.3d 696, 697 n.1 (2d Cir. 2009) (relying on Am. Compl. ¶¶ 2, 19. On June 7, 2018, Plaintiff met Doroudian (a resident of Vancouver, British Columbia) at a healthcare conference held at a hotel in New York. Id. ¶¶ 5, 20. At the time, Doroudian was the chairperson and chief executive officer of Altum, a Canadian biopharmaceutical start-up company focused on developing products to treat human papillomavirus (“HPV”) and cancer. Id. ¶¶ 3, 20. One of Doroudian’s goals was for Altum to obtain approval from the United States Food and Drug Administration (the “FDA”) to use interferon alpha-2b (“interferon”) to treat HPV. Id. ¶ 20.2

“Doroudian proposed that [Plaintiff] join Altum as a part-time consultant in the New York Metropolitan area to assist with fundraising, product development and sourcing [interferon] material from [Plaintiff’s] former employer.” Id. ¶ 23. Over the next two days, Plaintiff and Doroudian “exchanged emails and a form of agreement setting forth the material terms of the consulting arrangement, including a three-month term for $75,000 in compensation payable half in cash and half in Altum shares.” Id. On June 13, 2018, Doroudian emailed Plaintiff a copy of the consulting agreement for her to sign and return, which she did. Id. ¶ 24; see ECF No. 50-1 (the “Consulting Agreement”). Plaintiff “fully performed her obligations under the Consulting Agreement.” Am. Compl. ¶ 27. She was

unaware, however, that Doroudian was diluting the value of Altum’s stock; as a result, the stock payments to Plaintiff were worth far less than the $37,500 owed under the Consulting Agreement. Id. ¶ 26.

affidavits to resolve a forum non conveniens motion is “a practice long recognized as acceptable and followed from time immemorial in the busy Southern District of New York” (citation omitted)). 2 Interferon alpha-2b (also spelled interferon alfa-2b) is a “synthetic protein” that may help a person’s “immune system fight viral infections and certain cancer growths.” Interferon Alfa- 2b Injection, Cleveland Clinic, https://my.clevelandclinic.org/health/drugs/19584-interferon- alfa-2b-injection [https://perma.cc/5LDR-AF2L]. During the summer of 2018, Doroudian recruited Plaintiff to join Altum on a full-time basis, including as executive chairperson of its board of directors. Id. ¶¶ 28-29. Doroudian ultimately persuaded Plaintiff to join Altum, resulting in Plaintiff signing a written employment agreement in the fall of 2018. Id. ¶¶ 29, 31; see ECF No. 50-2 (the “Employment Agreement”). Under the Employment Agreement, Plaintiff’s “initial compensation was set at $410,000, including a $50,000 signing bonus payable in immediately

exercisable stock options, as well as $180,000 in salary, $80,000 in stock and $100,000 in options, each payable in equal quarterly installments.” Am. Compl. ¶ 33. Article 12 of the Employment Agreement, titled “GOVERNING LAW,” stated: This Agreement will be governed by and construed in accordance with the laws of the Province of British Columbia. Each of the parties hereby irrevocably attorns to the jurisdiction of the Courts of Vancouver, British Columbia, with respect to any disputes arising out of this Agreement. Employment Agreement § 12.1.3 Plaintiff “fully performed her obligations under the Employment Agreement.” Am. Compl. ¶ 34. Altum paid Plaintiff “for the last quarter of 2018 and all four quarters of 2019 as required, but thereafter failed and refused to make further salary payments without justification or explanation.” Id. ¶ 40. Altum was not Doroudian’s only company. He also co-founded BetterLife, a Canadian penny-stock cannabis company that shared a Vancouver address with Altum. Id. ¶¶ 3-4, 45.

Free access — add to your briefcase to read the full text and ask questions with AI

Miller-Rich v. Altum Pharmaceuticals Inc., (S.D.N.Y. 2023).

Miller-Rich v. Altum Pharmaceuticals Inc. (Miller-Rich v. Altum Pharmaceuticals Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

The Bremen v. Zapata Off-Shore Co.
407 U.S. 1 (Supreme Court, 1972)
Piper Aircraft Co. v. Reyno
454 U.S. 235 (Supreme Court, 1982)
Shearson/American Express Inc. v. McMahon
482 U.S. 220 (Supreme Court, 1987)
Van Cauwenberghe v. Biard
486 U.S. 517 (Supreme Court, 1988)
S.K.I. Beer Corp. v. Baltika Brewery
612 F.3d 705 (Second Circuit, 2010)
Reginald H. Howe v. Goldcorp Investments, Ltd.
946 F.2d 944 (First Circuit, 1991)
Allstate Life Insurance Co. v. Linter Group Limited
994 F.2d 996 (Second Circuit, 1993)
Alfadda v. Fenn
159 F.3d 41 (Second Circuit, 1998)
Madalynn Carey v. Bayerische Hypo-Und Vereinsbank Ag
370 F.3d 234 (Second Circuit, 2004)
Dotson v. Griesa
398 F.3d 156 (Second Circuit, 2005)
Jenkins v. City Of New York
478 F.3d 76 (Second Circuit, 2007)
Magi XXI, Inc. v. Stato della Città del Vaticano
714 F.3d 714 (Second Circuit, 2013)
Aguas Lenders Recovery Group LLC v. Suez, S.A.
585 F.3d 696 (Second Circuit, 2009)
Phillips v. Audio Active Ltd.
494 F.3d 378 (Second Circuit, 2007)
KTV Media International, Inc. v. Galaxy Group, LA LLC
812 F. Supp. 2d 377 (S.D. New York, 2011)
Jeffreys v. Griffin
801 N.E.2d 404 (New York Court of Appeals, 2003)